The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy

The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy

Abstract Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enr...

Full description

Bibliographic Details
Main Authors:	Hyunkyung Park, Ju‐Hee Bang, Ah‐Rong Nam, Ji Eun Park, Mei Hua Jin, Yung‐Jue Bang, Do‐Youn Oh
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Cancer Medicine
Subjects:	biomarker chemotherapy pancreatic cancer prognosis transforming growth factor‐beta
Online Access:	https://doi.org/10.1002/cam4.2677

Similar Items

Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer
by: Byung Soo Kwan, et al.
Published: (2023-05-01)

Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
by: Mariia Kiriukova, et al.
Published: (2020-09-01)

ELECTROCHEMOTHERAPY IN THE TREATMENT OF UNRESECTABLE PANCREATIC CANCER
by: A. A. Kovalev
Published: (2022-03-01)

Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients
by: Taira Kuroda, et al.
Published: (2017-05-01)

Brachytherapy Drainage Catheter and Chemotherapy for Unresectable Pancreatic Carcinoma Combined with Obstructive Jaundice
by: Dechao Jiao, et al.
Published: (2022-07-01)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
by: Changhoon Yoo, et al.
Published: (2019-02-01)

Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer
by: Shu‐Hui Lee, et al.
Published: (2019-07-01)

Pancreatic beta cell in health and disease /
by: Seino, Susumu, et al.
Published: (2008)

Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer
by: Sung Jun Ma, et al.
Published: (2018-11-01)

The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
by: Ryoji Takada, et al.
Published: (2021-09-01)

Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor
by: Hsin-Han Yang, et al.
Published: (2021-07-01)

Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
by: Naoto Iwai, et al.
Published: (2021-07-01)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
by: Takuo Yamai, et al.
Published: (2022-04-01)

Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy
by: Maozhen Peng, et al.
Published: (2023-04-01)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
by: Sumana Devata, et al.
Published: (2012-11-01)

Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
by: Kamil D. Dalgatov, et al.
Published: (2021-08-01)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01)

Is intraperitoneal chemotherapy beneficial in pancreatic cancer?
by: Irina Balescu, et al.
Published: (2022-06-01)

Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy
by: Richard Fischer, et al.
Published: (2012-01-01)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01)

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer
by: Juan Du, et al.
Published: (2022-11-01)

Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer
by: Zehua Zhang, et al.
Published: (2024-02-01)

Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
by: Yanfen Zheng, et al.
Published: (2022-06-01)

The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study
by: Hyun yeb Jung, et al.
Published: (2022-04-01)

Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome
by: Harika Nalluri, et al.
Published: (2021-10-01)

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
by: Gregory P. Botta, et al.
Published: (2023-04-01)

COMBINATION CHEMOTHERAPY REGIMENS IN PANCREATIC CANCER
by: A. S. POPOVA, et al.
Published: (2017-06-01)

Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer
by: Shalini Moningi, et al.
Published: (2022-07-01)

Analysis of the efficacy of transcatheter arterial infusion chemotherapy in the treatment of pancreatic carcinoma
by: Chunhui Nie, et al.
Published: (2021-02-01)

Adjuvant Chemo-Radiotherapy versus Chemotherapy in Pancreatic Carcinoma
by: Shimaa Attia, et al.
Published: (2017-06-01)

The Interplay of Adipokines and Pancreatic Beta Cells in Metabolic Regulation and Diabetes
by: Joon Kim, et al.
Published: (2023-09-01)

It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
by: Ingrid Garajová, et al.
Published: (2022-06-01)

The underlying molecular mechanism of intratumoral radiofrequency hyperthermia-enhanced chemotherapy of pancreatic cancer
by: Liangcai Zhao, et al.
Published: (2022-05-01)

Impact of Baseline Muscle Mass and Myosteatosis on the Development of Early Toxicity During First-Line Chemotherapy in Patients With Initially Metastatic Pancreatic Cancer
by: Sun Hong, et al.
Published: (2022-05-01)

TGF Beta Induces Vitamin D Receptor and Modulates Mitochondrial Activity of Human Pancreatic Cancer Cells
by: Camilla Fiz, et al.
Published: (2021-06-01)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
by: Volker Kunzmann, et al.
Published: (2014-09-01)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
by: Sumit Sahni, et al.
Published: (2023-09-01)

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
by: Alessandro Bittoni, et al.
Published: (2021-09-01)

Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study
by: Masatoshi Murakami, et al.
Published: (2022-01-01)

Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?
by: Nathalie Rosumeck, et al.
Published: (2021-01-01)